Long-acting (LA) glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) that require injection once a week or less are now available to prescribers in the form of Bydureon®(once-weekly exenatide).

Once-weekly taspoglutide was superior to twice-daily ... and hypersensitivity reactions. Clearly, GLP-1 receptor agonists may not be appropriate for all patients with type 2 diabetes, as they ...

However, interest in GLP-1 drugs, particularly Ozempic, has also been fueled in part by social media discourse and ...

Once-weekly semaglutide shows significant reduction in knee osteoarthritis pain and body weight in adults with obesity, a ...

Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months ... loss come as shots that users give ...

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

As the GLP-1 class has taken over in recent years, a once-fringe conference has come into the spotlight for the biopharma industry. ObesityWeek, which started in 2013, attracted ...

Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of drug-enhancing technology.

Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...